Next Fiscal Year Forecasted Results:
Sales $5,000
Cost Of Sales 3,400
-------
1,600
PMC Research $300,000
Lisence Fees 0
Royalties 35,000
--------
$336,600
R & D (500,000)
Admin. (1,300,000)
Occupancy (190,000)
----------
$(1,990,000)
Oper Loss $(1,653,400)
============
Loss/Share $(.07)
======
ASSUMPTIONS:
24.3 million shares outstanding
I left out any possible additional cash payments from IMNX because they don't have any affect on the stock price.
I am assuming that Techne can increase sales of CIST's reagents by 20%, but is only paying a 5% royalty (very generous).
I am also assuming that somebody will be let go -- marketing maybe. |
